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Abstract
Nanoparticle drug formulations have been extensively researched and developed in the field of
drug delivery as a means to efficiently deliver insoluble drugs to tumor cells. By mechanisms of
the enhanced permeability and retention effect, nanoparticle drug formulations are capable of
greatly enhancing the safety, pharmacokinetic profiles and bioavailability of the administered
treatment. Here, the progress of various nanoparticle formulations in both research and clinical
applications is detailed with a focus on the development of drug/gene delivery systems.
Specifically, the unique advantages and disadvanges of polymeric nanoparticles, liposomes, solid
lipid nanoparticles, nanocrystals and lipid-coated nanoparticles for targeted drug delivery will be
investigated in detail.
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1. Introduction
Over the past two decades, nanomedicine has emerged as a catalyst for the advancement of
new pharmaceutical formulations (Ferrari, 2005; Panyam and Labhasetwar, 2003; Shi et al.,
2010). By permitting the dispersion of insoluble drugs in aqueous solution, many drugs
previously abandoned due to their poor solubility in water can be deemed clinically
applicable through encapsulation in a nanocarrier. Nanomedicine can also improve the
pharmacokinetics (PK) and biodistribution of drugs that have already been approved for use
by the Food and Drug Administration (FDA) (Emerich and Thanos, 2007; Sahoo and
Labhasetwar, 2003). By favorably altering the PK of drugs in vivo, nanomedicine can
significantly improve the safety of existing chemotherapy regimens.
Several strategies have been successfully developed to formulate nanoparticles (NPs)
containing insoluble drugs. Polymers, such as poly (d,l-lactide-co-glycolide) (PLGA) (Bala
et al., 2004; Cheng et al., 2007), polylactides (PLA) (Smith, 1986; Soppimath et al., 2001)
and polycaprolactone (PCL) (Cai et al., 2007; Park et al., 2005), encapsulate hydrophobic
© 2013 Elsevier Inc. All rights reserved
*Address correspondence to: Dr. Leaf Huang, Division of Molecular Pharmaceutics, and Center for Nanotechnology in Drug
Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA. leafh@unc.edu, Tel.: + 1 919
843 0736; fax: + 1 919 966 0197.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript













drugs through hydrophobic interactions. Through these methods, efficient delivery of both
paclitaxel and docetaxel has been achieved (Fonseca et al., 2002; Hrkach et al., 2012).
In addition, liposomes may also be exploited for targeted drug delivery and have been
established as the most successful drug carriers marked by their biodegradability and ability
to deliver drugs with a wide range of physical properties. More than ten liposomal
formulations have been approved for use by the FDA and/or other regulatory authorities and
several additional liposomal formulations are currently in clinical trial (Wang et al., 2012).
Significant effort is also being made to deliver drugs using inorganic nanoparticles. The
development of these nanoparticulate formulations will be reviewed and summarized in
Table 1 and Table 2.
2. Polymeric nanoparticles
Polymeric nanoparticles can be synthesized through various methods depending on the
intended application and drug type. These methods include emulsion diffusion,
nanoprecipitation and emulsion evaporation (Jain, 2000; Kumari et al., 2010; Vauthier and
Bouchemal, 2009). However, the majority of polymeric nanoparticles are formulated
through a self-assembly process using hydrophilic and hydrophobic block copolymers
(Adams et al., 2003; Rösler et al., 2001). During the self-assembly of polymeric
nanoparticles, the hydrophobic drugs are encapsulated into the core of core-shell nano-
structure via hydrophobic interactions. Typically, the final nanoparticles created from this
method are 100–200 nm in diameter (Lalatsa et al., 2012; Wang and Grayson, 2012).
Polymeric nanoparticles act as drug depots characterized by controlled release of the
encapsulated drug. Modification of the nanoparticles with a surface coating of polyethylene
glycol (i.e. PEGylation), enables the nanoparticles’ evasion of the reticuloendothelial system
(RES) and prolongs circulation in the bloodstream (Esmaeili et al., 2008). This capability,
along with the biocompatibility and low immunogenicity of these nanoparticles make them
an attractive delivery system, particularly for protein-based and anti-cancer drugs, as well as
nucleic acids.
Among the polymers, PLA and PLGA, have been the most extensively investigated for use
in drug delivery due to their biocompatibility and controlled release through the hydrolysis
of the ester bonds (Li et al., 2011; Makadia and Siegel, 2011). By adjusting the composition
of PLGA through alteration of the ratio between lactide and glycolide, the release rate of
drugs can be adjusted from a scale of days to months (Amann et al., 2010; Faisant et al.,
2002; Ramchandani and Robinson, 1998). However, there are only a few polymeric
nanoparticulate formulations on the market. One of them, paclitaxel-loaded nanoparticles
(Genexol-PM®) composed of an amphiphilic diblock copolymer, monomethoxy-
poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLLA) and paclitaxel is approved
for the treatment of breast and lung cancers in Asia (Lee et al., 2008b; Lim et al., 2010). The
data demonstrated that Genexol-PM® showed significant antitumor activity with an
increased maximum tolerated dose thus allowing the administration of higher doses of
paclitaxel. Genexol-PM® has also been combined with gemcitabine and cisplatin to treat
patients with advanced urothelial cancer in Phase II clinical studies (Lee et al., 2012a).
Additionally, Phase I clinical trial have been completed on PEG-PLGA-PMSA-targeted
polymeric NPs loaded with Docetaxel (BIND-014) (Cartwright, 2013; Prabhakar et al.,
2013; Wang, Langer, 2012). The trial have indicated that the formulation is safe with a
reasonable maximum tolerated dose and notable anti-tumor activity. A similar formulation
of a docetaxel-polymeric micellar nanoparticle formulation (Docetaxel-PNP) is currently
under development by Samyang Pharmaceuticals undergoing Phase I clinical trial to treat
advanced solid malignancies in Korea (Miller and Wang, 2013; Svenson, 2012).
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In the United States, non-biodegradable poloxamer is approved by the FDA and has been
widely used to develop nanomedicines (Chang et al., 2011; Schmolka, 1991). SP1049C,
composed of poloxamer and doxorubicin (Valle et al., 2011) is particularly active in treating
multidrug resistant (MDR) and metastatic cancers (Danson et al., 2004; Dumortier et al.,
2006); the poloxamer disrupts mitochondrial functionality in chemo-resistant cells by
depleting ATP and releasing reactive oxygen species (ROS) and cytochrome C. Currently,
SP1049C is advancing to an international Phase III clinical study. Likewise, similar
formulations containing docetaxel (SP1012C) and cabazitaxel (SP1015C) are being
evaluated in preclinical studies (Svenson, 2012).
Kataoka et al. esterified a PEG-polyaspartate block copolymer using 4-phenyl-1-butanol to
enhance the hydrophobicity of copolymer and its compatibility with paclitaxel (Negishi et
al., 2006). The amphiphilic copolymer was used to construct a micellar paclitaxel (PTX)
formulation named NK105. For the micellar drug formulation, NK105 was characterized
with a drug loading of 23wt%. It has been observed that PEGylation significantly improves
the area-under-curve (AUC) values in the blood and in the tumor by 90- and 25- fold,
respectively, compared to free drug. NK105 showed superior anti-tumor efficacy and
reduced neurotoxicity when compared with free PTX. Results from Phase I clinical studies
showed that NK105 was well tolerated (Hamaguchi et al., 2007). Efficacy and safety studies
in Phase II clinical trial showed that NK105 was very efficacious in treating patients with
previously treated advanced gastric cancer (Ko et al., 2013). Due to the success of this
formulation, a Phase III clinical trial of NK105 is currently underway.
Another promising polymeric nanoparticle formulation is nab-paclitaxel (Abraxane) (Green
et al., 2006; Miele et al., 2009). Abraxane is an albumin-bound paclitaxel nanoparticle
specifically designed to replace Taxol in an effort to reduce the highly toxic side effects
induced when Taxol is formulated in a 1:1 (v:v) mixture of Cremophor EL and dehydrated
alcohol. Compared to Taxol, Cremophor®-free Abraxane decreases the both the number and
severity of side effects induced by paclitaxel (Micha et al., 2006). Clinical results show that
Abraxane also induces higher response rates and shows prolonged tumor suppressive
activity without increased toxicity in patients with metastatic breast cancer. In light of these
discoveries, the FDA approved Abraxane for clinical use in January 2005. Thereafter,
several drug-albumin nanoparticulate formulations were developed based on the same
technology and are currently advancing to clinical trials.
In a Phase I/II study, Abraxane was combined with gemcitabine to treat pancreatic cancer.
The combination showed significant anti-pancreatic cancer efficacy with a 48% response
rate observed at MTD. This study also indicated the significance of SPARC up-regulation,
which was reported to dictate the uptake of drugs into tumor cells and is primarily
responsible for the tumor’s sensitivity to drug treatment. It was hypothesized nab paclitaxel
significantly enhanced the bioavailability of gemcitabine inside tumors through Abraxane
targeting to deplete stroma and therefore enhance the penetration of gemcitabine inside the
pancreatic cancer cells (Neuzillet et al., 2013; Von Hoff et al., 2011). Recently disclosed
data from the Phase III clinical study demonstrated that the combination permitted a
significant improvement in efficacy and response rate over free gemcitabine alone (Von
Hoff et al., 2012).
3. Polymer-drug conjugate nanoparticles
Although polymeric nanoparticles have shown promising potential for drug delivery, the
achievable drug loading in polymeric nanoparticles varies significantly and limits the broad
application of this versatile platform. To maximize the loading of drugs in polymeric
nanoparticles, the drug and carrier must be perfectly matched in miscibility (Liu et al., 2004;
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Xiong et al., 2011). Many efforts have been made to modify the polymer backbone with an
aim of improving the miscibility between drugs and carriers evaluated using the Floury–
Huggins interaction parameter (χdrug/polymer). It is believed that a smaller interaction
parameter indicates a higher miscibility between the drug and carrier. In addition, the drug
loading of a polymeric nanoparticle formulation can be greatly enhanced through variation
of the select polymer’s side group. Unfortunately for FDA approved poly(lactic-co-glycolic)
acid (PLGA) NPs, the available options for modification are greatly limited as the polymer
contains only one functional terminal group. In an effort to maximize the drug loading
capacity of polymeric nanoparticles while enhancing miscibility and biocompatibility, a
polymeric drug conjugate has been developed as an alternative method.
In the same method that amphiphilic polymers are capable of undergoing self-assembly into
core-shell nanoparticle formulations hydrophilic copolymers conjugated with hydrophobic
drugs become amphiphilic and can be self-assembled into nanoparticles. To date, the most
often-used hydrophilic polymers are HPMA (Duncan et al., 2001; Kopeček et al., 2000),
Dextran (Kojima et al., 1980; Mitra et al., 2001) and poly-glutamic acid (Li, 2002; Singer et
al., 2004). Several conjugates based on these copolymers are under clinical evaluation, such
as PK1 (Seymour et al., 2009), Xyotax™ (Opaxio™ or CT-2103) (O'Brien et al., 2008),
CT-2106 (Homsi et al., 2007), Delimotecan (MEN 4901/T-0128) (Veltkamp et al., 2008)
and DOX-OXD (AD-70) (Danhauser-Riedl et al., 1993). Kopecek and colleagues first
developed the HPMA–doxorubicin conjugate with a drug loading capacity of approximately
8wt.%(Duncan et al., 1987). Later, HPMA–doxorubicin (PK1, FCE28068) entered into a
Phase II clinical trial (Seymour et al., 2009). Additionally, a biodegradable, polyglutamic
acid-paclitaxel conjugate with a drug content of 37wt.% has also been synthesized (Auzenne
et al., 2002; Li et al., 1998)and conjugates of PGA with camptothecin were developed and
are currently under clinical evaluation (Bhatt et al., 2003; Homsi, Simon, 2007). However,
with the exception of PGA–paclitaxel conjugates (Xyotax), polymer-drug conjugates are
often plagued by the slow release of active drugs and the subsequent side effects as observed
in clinical trial (Li and Wallace, 2008; Lin et al., 2007; Sabbatini et al., 2004). Despite the
advantages, Xyotax can only improve the rate of cancer survival in women, but not in men
(Ross et al., 2006). This result may be because estrogen promotes the degradation of the
backbone of polyglutamic acid (Ross, Bonomi, 2006). These findings therefore inspired the
development of conjugates for controlled drug release. Thereafter, many efforts have been
made to tailor the conjugate using pH-sensitive or enzyme degradable linkers (Duncan,
2006; Saito et al., 2003).
Albumin is a very promising material for use in drug delivery due to its biodegradability and
availability, as well as its non-immunogenic nature. Resulting from these properties,
albumin has demonstrated preferential uptake by both tumor and inflamed tissues (Elzoghby
et al., 2012; Kratz, 2008). Methotrexate-albumin conjugate (MTX-HSA) was the first
albumin conjugate that was evaluated in Phase I/II clinical studies (Bolling et al., 2006;
Hartung et al., 1999; Vis et al., 2002). However, there has been no further progress in
examining the effects of this conjugate. In addition, Kratz et al. synthesized a series of drug-
albumin conjugates using enzymatically cleavable peptide linkers to achieve conjugates with
precise structures. Some examples include doxorubicin-albumin-, methotrexate-, and
camptothecin-conjugates which are each cleaved by a unique combination utilizing two to
three of the following: matrix metalloproteases 2 and 9, cathepsin B, urokinase, prostate-
specific antigen (PSA), plasmin or proteases (Kratz, 2008; Warnecke et al., 2007).
Davis et al. developed a cyclodextrin-containing polymer-camptothecin (CPT) drug
conjugate where 10wt% of CPT was conjugated to the polymer through the glycine amino
acid linker with minimal side effects (Cheng et al., 2003). The drug was conjugated via self-
assembly to form nanoparticles. The formulation (formerly called IT-101, now CRLX101)
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has an average size between 30–40 nm. The slightly negatively charged IT-101 showed a
plasma half-life of about 24 h in blood circulation and significant tumor accumulation within
the first 24h following IV injection (Schluep et al., 2006a; Schluep et al., 2006b; Schluep et
al., 2009). Preclinical data showed that a single IV dose of IT-101 (18.3 mg eq. CPT/kg)
exhibited comparable efficacy to three weekly doses of Irinotecan (100 mg/kg IP) with
significantly lower toxicity. Data from Phase I clinical trial reported that the half-life of
IT-101 in subjects was ∼40 h while the formulation also improved the tolerability and
efficacy towards CPT (Svenson et al., 2011). A Phase II clinical trial of IT-101 is currently
underway.
Recently, Li et al. (Ernsting et al., 2012a; Ernsting et al., 2012b) developed a docetaxel-
acetylated carboxymethylcellulose drug conjugate (Cellax). The drug conjugate was
characterized with a drug loading of 37.3wt% and was able to form nanoparticles via self-
assembly. Preclinical data has shown that PEGylated Cellax has extended circulation time in
the blood over Abraxane and no significant drug release in the blood was observed. Cellax
showed significantly higher tumor accumulation than Abraxane through the EPR effect. One
single IV injection of Cellax significantly suppressed the growth of a panel of primary and
metastatic tumors and extended the survival of tumor bearing mice without observable
adverse effects. A further study of the mechanism behind the anti-tumor effects showed that
Cellax can reduce the content of α-smooth muscle actin (α-SMA), which is a marker of the
cancer-associated fibroblasts, in 4T1 and MDA-MB-231 orthotopic breast tumor models
(Murakami et al., 2013). Cellax treatment significantly decreased the tumor IFP. As a result,
perfusion of active drugs into tumors was significantly enhanced resulting in tumor growth
inhibition. These studies indicated the importance of overcoming stroma-induced barriers in
cancer treatment.
4. Liposomal formulation
As described by Bangham in 1964 (Bangham and Horne, 1964), liposomes formed from
amphiphilic phospholipids and cholesterol became one of the first nanoparticulate platforms
for drug delivery. When the lipid film is hydrated, the hydrophobic drugs can be
successfully incorporated in a bilayer of liposomes. Additionally, the liposomes may be used
to encapsulate water-soluble drugs into the internal aqueous core. By varying the
combination of lipids used in formulating the nanoparticles, the biodistribution in vivo can
be precisely adjusted to optimize tumor accumulation.
PEGylation is the most effective method for reducing protein adsorption in vivo and can
successfully facilitate the particles’ avoidance of the RES system to prolong their circulation
in the bloodstream (Guo and Huang, 2011; Klibanov et al., 1990). PEG-lipids (e.g. PEG-
DSPE) are usually inserted into the liposomes to form a hydrated layer on the liposome
surface. Typically, liposomes can improve a drug’s pharmacokinetics and biodistribution.
Liposomes that are 100–200 nm in diameter readily accumulate in the tumor interstitium
because of the enhanced permeability and retention (EPR) effect (Fang et al., 2011; Maeda
et al., 2000). The EPR effect is also facilitated by the lack of a draining lymphatic system in
the tumor tissue.
Doxorubicin is loaded into liposomes using remote loading technology (Barenholz, 2012;
Fritze et al., 2006). The loaded drug crystalizes inside the liposomes due to low solubility
and high concentration. In patients, Doxil (liposomal doxorubicin) prolongs the circulation
of doxorubicin, as well as increases its concentration in the tumors while decreasing its
concentration in normal tissues, such as the heart (Gabizon et al., 2003). Doxil significantly
decreases the cardio-toxicity of doxorubicin and showed comparable anti-tumor efficacy
with doxorubicin in many types of cancer. Following the success of Doxil (Barenholz,
Guo and Huang Page 5













2012), the FDA approved non-PEGylated doxorubicin liposomal formulation DaunoXome
(Fassas and Anagnostopoulos, 2005) and Myocet (Leonard, Williams, 2009) for cancer
therapy. There are more than 11 additional formulations approved for clinical use, with
many more in clinical and preclinical development (Duffaud, Borner, 2004; Ko, Tempero,
2013; Koudelka and Turanek, 2012; May and Li, 2013; Roy, Park, 2013; Svenson, 2012;
Tagami et al., 2012; Wang, Langer, 2012). Among them, ThermoDox is a very promising
doxorubicin formulation and currently undergoing Phase III clinical trial for the treatment of
hepatocellular carcinoma (Dromi, Frenkel, 2007). In this formulation, the release of
Doxorubicin is triggered by hyperthermic treatments.
NX 211 is a liposomal formulation of lurtotecan and was formulated with methodology
similar to that of DaunoXome (Emerson et al., 2000). Clinical Phase II results indicated
minimal anti-cancer activity in topotecan resistant ovarian cancer (Seiden et al., 2004).
MM-398 (PEP02) is a liposomal nanocarrier formulation of irinotecan. A negatively
charged sucrose octasulfate in interior aqueous Phase of liposomes formed electrolytes
complexes with positively charged irinotecan and therefore assist the drug loading
(Drummond et al., 2006). In clinical Phase II trial, MM-398 extended the median survival of
patients who had failed treatment with gemcitabine (Ko, Tempero, 2013; Roy, Park, 2013).
Currently, MM-398 is advancing to Phase III to treat patients with gemcitabine (GEM)-
refractory metastatic pancreatic cancer with combination of 5-fluorouracil and leucovorin.
In addition, a liposomal paclitaxel formulation, LEP-ETU, is also developed (Straubinger
and Balasubramanian, 2005). Paclitaxel is entrapped within the liposomal hydrophobic
phospholipid bilayers. In Phase I study, LEP-ETU improved the MTD of paclitaxel
compared with Taxol®. Phase II trial in treating patients with metastatic breast cancer
indicated the safety and efficacy of LEP-ETU (Koudelka and Turanek, 2012).
5. Solid lipid nanoparticles
Due to limited space within the bilayer of the liposomes, most of liposomal formulations are
characterized by low drug loading. To overcome this issue, solid lipid nanoparticles (SLNs)
were developed (Mehnert and Mäder, 2001; Müller et al., 2000). The solid lipid
nanoparticulate formulations have many advantages, such as increased safety, high stability
and ease of industrial scale-up. SLNs are made of solid lipids, emulsifiers, the encapsulated
drugs and water. Generally, the lipids are triglycerides, partial-glyceride–fatty acids, steroids
and waxes. A variety of emulsifiers have been used to stabilize the lipid dispersion. SLNs
can be prepared by high-pressure homogenization (HPH), high shear mixing, and ultrasound
or solvent emulsification/evaporation methods. Many different drugs have been incorporated
into SLNs. For example, SLNs formulated with piribedil, vinpocetine and cyclosporine A
for oral delivery have a high capacity of drug loading, improving the bioavailability of these
drugs (Swathi et al., 2012). Similarly, ubidecarenone’s loading capacity can be up to 50%
(Bunjes et al., 2001). Battaglia et al. has also demonstrated SLNs are able to encapsulate
methotrexate (Battaglia et al., 2011). In vivo, SLNs enhance the accumulation of drugs in the
tumor and increase the therapeutic effects. Although SLNs are being exhaustively used as a
platform to deliver hydrophobic anticancer drugs, preclinical research is still being
conducted on their properties and effects.
6. Lipid coated Calcium Phosphate (LCP) nanoparticles
The applications of nanomedicine are hampered by the low stability and rapid blood
clearance of the particles in vivo. For the liposomes, PEG-lipid (such as PEG-DSPE) is
usually inserted into liposomes to form a hydrophilic layer on the liposome surface to avoid
RES. When inserted, the PEG takes mushroom conformation at low densities and a brush
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conformation at higher densities of DSPE-mPEG (Huang and Liu, 2011). The brush mode is
the ideal configuration for protecting nanoparticles from serum absorption. Unfortunately, a
high content of the detergent-like PEG-lipid will lyse the liposome. A supporting lipid-
bilayer and the proper density of PEGylation stabilizes the nanoparticle in the blood and
enables the evasion of the RES (Li and Huang, 2009).
Calcium phosphate (CaP) is a natural and biocompatible material. Its acid sensitivity allows
the release of the entrapped cargo from the acidic endosome into the cytoplasm. Inorganic
CaP NPs can be synthesized through the reaction between calcium and phosphate ions.
However, the size and stability of CaP NPs are very difficult to control. Recently,
microemulsions have been used as a reactor to synthesize CaP NPs (Muddana et al., 2009),
but the NPs were purified using HPLC, process that is tedious and difficult to complete
during scale-up. However, when attempting to purify the nanoparticles using a precipitation
method, the NPs tend to aggregate with the addition of ethanol. In order to prevent
aggregation, we innovatively synthesized lipid-coated CaP NPs (Li et al., 2010; Li, Yang,
2012). During the synthesis of NPs, an amphiphilic, anionic lipid, DOPA, was added into
the microemulsion (As shown in Figure 2). The amphiphilic DOPA stays at the interface of
the microemulsion and interacts with the synthesized CaP NPs through binding with the
surface of NPs. The NPs are then coated with a layer of lipids. DOPA-coated CaP NPs can
be purified in a manner similar to that of quantum dots and iron oxide nanoparticles, in
particular, and exhibit similar solubility.
The DOPA-coated CaP NPs are freely dispersed in hexane, toluene and chloroform and can
be stabilized in aqueous solution by DSPE-PEG and other lipids, such as DOTAP, DOPC
and cholesterol. During preparation, anionic imaging agents, nucleic acids (DNA and
siRNA) and drugs can be incorporated into the CaP NPs, indicating the theranostic potential
of this delivery mechanism (Yang et al., 2011; Zhang et al., 2013). For the delivery of
siRNA, the ED50 of LCP NPs encapsulated with HDM2/c-myc/VEGF siRNA is ∼0.2 mg/kg
in A549 tumors (Yang, Li, 2011). The combination of the silencing of HDM2/c-myc/VEGF-
inhibited tumor proliferation and angiogenesis induces tumor apoptosis. In addition, the
bioactive form of gemcitabine, gemcitabine triphosphate (GTP), was efficiently loaded into
the LCP NPs (Figure 3) (Zhang, Kim, 2013). Therapeutic studies show that anisamide-
targeted LCP NPs loaded with GTP effectively delayed tumor growth in human NSCLC
H460 and pancreatic BxPC-3 cancer xenografts, with little toxicity in vivo. This LCP NP
platform may inspire the delivery of many more chemo drugs modified with phosphate
groups to bypass the kinase phosphorylation process, enabling more potent activity.
7. Nanocrystals
To eliminate potential toxicity from the carrier and improve the maximum tolerable dose
(MTD), nanocrystals have been developed using the chemo-drugs (Chen et al., 2011;
Junghanns and Müller, 2008). The nanocrystals have a size in the nanometer range and
crystalline characteristics. The drug loading of the nanoparticles is nearly 100%. There are
two major methods used to synthesize nanocrystals, i.e., “top-down” and “bottom-up”
methods.
“Bottom-up” methods involve self-assembly in nano-scale (De Waard et al., 2008).
Nanoprecipitation is the most popular way to produce nanocrystals; the crystals grow from
the nucleation (Gao et al., 2008; Muller and Keck, 2004). Typically, drugs are solubilized in
a water miscible solvent, such as a combination of acetone, THF and ethanol, at a level of
super saturation in the water. This process allows the rapid formation of nucleation after the
water has been added. After the addition of the antisolvent, the nanocrystals are formed with
the aid of a stabilizer, such as polyvinylpyrrolidone, Tween 80, Poloxamer 188 or lecithin.
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The stabilizer will inhibit the aggregation of nanocrystals. A second precipitation method is
the preparation of amorphous, drug nanoparticles, which was developed by Auweter and
Horn (Auweter et al., 1998). The amorphous nanoparticles are prone to partial or complete
re-crystallization, resulting in decreased bioavailability. Due to the stability and consistent
performance, nanocrystals are preferred over amorphous drug particles. Another bottom–up
process is the controlled crystallization of the particles during freeze drying (De Waard,
Hinrichs, 2008), which is also considered to be suitable for large-scale production (de Waard
et al., 2009).
“Top-down” involves breaking down large drug particles into smaller particles through
milling or HPH (Keck and Müller, 2006). In 1992, Liversidge et al. applied milling
technology to produce drug particles (Liversidge et al., 1992). The milling chamber is
charged with milling pearls, dispersion medium (e.g. water), drug powders and stabilizers.
The pearls rotate at a very high speed to generate particles of small sizes. However, erosion
from the milling material during the milling process leads to contamination of the drugs.
Compared to the manufacture of other nanomedicines, the milling technology allows much
larger scale-up production of drug particles and the FDA has approved several formulations
that are created with this method.
The development of Dissocubes1 piston-gap homogenizer (SkyePharma) in the mid-1990s
has accelerated the application of HPH in the pharmaceutical industry (Keck and Müller,
2006). Typically, HPH is performed in either water or PEG 400. The non-aqueous media is
preferred in the creation of particles with water sensitive drugs. The suspension of
crystalline drugs and stabilizers is passed through the homogenizer at high pressure (500–
2000 bar). The size of the particles is influenced by the stabilizers, the number of cycles and
the pressure and temperature of the homogenization process. By increasing the
homogenization pressure and the number of homogenization cycles, smaller nanocrystals
can be obtained. Stabilizers are used to avoid the aggregation of nanocrystals. To date,
Triglide1 has been approved for the treatment of hypercholesterolemia or hyperlipidemia
(Tziomalos and Athyros, 2006). In addition, Nanopure, Nanocrystal™, Nanomorph™ and
Nanoedge™ have been developed (Keck and Müller, 2006).
Compared to intravenous route, oral administration has higher patient compliance and
higher market potential. Several nanocrystal formulations have been approved by FDA as
oral products. For oral administration, bioavailability of hydrophobic drugs highly depends
on the dissolution rate and its diffusion through the gastrointestinal membranes to the
bloodstream. One of the major advantages of nanocrystal in oral delivery is the enhanced
solubility of drug and faster dissolution of the nanocrystals due to its high surface-area-to-
volume ratio, which can be well explained by Noyes–Whitney equation (Noyes and
Whitney, 1897; Shegokar and Muller, 2010). In addition, nanocrystals are biological
membrane adhesive and can extend the retention of drug in the gastrointestinal tract. These
nanocrystal formulations improved the bioavailability of drug (Shegokar and Muller, 2010).
For example, bioavailability of Wellvone was improved 2.5-fold by administration in
atovaquone nanosuspension (Scholer et al., 2001), and Danazol improved the bioavailability
of marketed danazol macrosuspension by 15.8 fold(Liversidge and Cundy, 1995). Yet, none
of cancer nanocrystal formulations has been approved by FDA (Sun and Yeo, 2012). 2-
Methoxyestradiol is a natural metabolite of estradiol, targets new blood vessels in tumor and
shows anti-angiogenesis effects. It has been formulated as nanocrystal Panzem®NCD and
Panzem®NCD enhanced the bioavailability of 2-Methoxyestradiol (Tevaarwerk et al.,
2009). In Phase II clinical trial, Panzem®NCD was orally administered in combination with
bevacizumab or sunitinib to treat metastatic carcinoid tumors (Bruce, Eickhoff, 2012; Kulke,
Chan, 2011). However, Panzem®NCD alone, or in combination, did not induce strong
response in patients. Thymectacin, an anticancer prodrug of brivudine monophosphate, is
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formulated as Theralux™ and being investigated in a Phase I/II trial (Shegokar and Muller,
2010).
8. Inorganic nanoparticles
Inorganic nanoparticles, such as magnetic iron oxide nanoparticles, quantum dots and
carbon nanotubes, are very attractive for use in drug delivery because of their dual function
in diagnosis and therapeutic effect (Sun et al., 2008; Xu et al., 2006).
Iron oxide nanoparticles (IONPs) are nanocrystals made from magnetite or hematite and
used as MRI contrast agents (Chertok et al., 2008). Usually, the synthesized IONPs have a
thick alkyl coating and are hydrophobic. After ligand exchange, the surface of IONPs can be
functionalized for PEGylation and conjugation with drugs and targeting ligands. For
instance, methotrexate (MTX), etoposide, doxorubicin and paclitaxel were successfully
conjugated, attached or encapsulated into the IONPs for potential treatment of tumors (Hwu
et al., 2008; Peng et al., 2008). Kohler et al. delivered methotrexate (MTX) using IONPs to
treat breast and brain tumor cells (Kohler et al., 2005). Labhasetwar et al. prepared a
doxorubicin/oleic acid (OA)-pluronic-coated iron oxide magnetic nanoparticle formulation
(Figure 4) (Jain, Morales, 2005). The doxorubicin was encapsulated into the alkyl layer of
oleic acid via hydrophobic interactions. The release of doxorubicin can be controlled and the
presence of doxorubicin does not interfere with the magnetization properties of IONPs.
Similarly, Sahoo et al. demonstrate mono-oleate-coated, magnetic nanoparticles (GMO-
MNPs) can dually deliver paclitaxel and Rapamycin. With the help of the alkyl chain,
∼95% encapsulation efficacy and 9.5% loading efficacy was achieved by these particles.
When modified with HER2 antibody as a targeting ligand, GMO-MNPs showed enhanced
uptake and cell toxicity in human breast carcinoma cell line (MCF-7) (Dilnawaz et al.,
2010).
Quantum dots (QDs) are made from semiconductor materials and have unique optical
properties, for example, they are much brighter and more stable than organic dyes. The
spectrum of QDs can be simply and accurately tuned according to their size. A very similar
strategy with IONPs was taken to allow the conjugation of drugs with the NPs.
Gold NPs (AuNPs) provide promising optical contrast agents as a result of their size and
optical properties (Kim et al., 2007). AuNPs with different shapes, such as nanospheres,
nanocages and nanorods have been investigated as contrast agents. AuNPs are highly
attractive platforms for the delivery of drugs to targeted tissues and cells. The drugs can be
loaded into the AuNPs through covalent conjugation or non-covalent association (e.g. high
drug loading of paclitaxel was achieved through conjugation of paclitaxel and AuNPs).
Gibson et al. conjugated paclitaxel with mercaptophenol-functionalized gold nanoparticles
through an oligoethylene glycol spacer using carbodiimide-based esterification chemistry
(Figure 5) (Gibson, Khanal, 2007). Hwu et al. synthesized paclitaxel-PEG-thiol at the C-2
position using a degradable phosphodiester linkage and attached it to the surface of citrate-
capped, gold nanoparticles or maleimide-coated, magnetite nanoparticles (Hwu, Lin, 2008).
The release of the drugs from the NPs is triggered by phosphodiesterases in cancer cells and
there is no release of drug in the serum. Similarly, to increase the solubility of paclitaxel,
Mirkin et al. attached paclitaxel-oligonucleotide-thiol conjugated on to the surface of gold
nanoparticles (Lee et al., 2008a). These nanoparticles enhanced the cytotoxicity of paclitaxel
in paclitaxel-sensitive and resistant cells. Additionally, the hydrophobic layer on the surface
of AuNPs was utilized for the solubilization of hydrophobic drug through hydrophobic
interaction by Rotello et al. (Kim et al., 2009). These methods provide a simple and versatile
method for drug delivery using AuNPs and may inspire more work with other type of
theranostic NPs to deliver drugs using the same strategy.
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Nanomedicine has shown tremendous therapeutic potentials to treat a variety of diseases for
both research and clinical applications. Several nanoparticulate formulations, such as Doxil
and Abraxane, have been approved by the FDA to treat cancers and have significantly
improved the safety of the drugs that are delivered. However, the efficacy of these
formulations for cancer therapy has not advanced to an appropriate degree. In the past
several decades, development of nano-formulations is particularly focused on the improving
the stability and pharmacokinetics of drug formulation and enhancing the targeting delivery
of formulations. However, abnormalities in tumor, such as growth induced solid stress,
abnormal blood vessel networks, elevated interstitial fluid pressure (IFP) and dense
interstitial structure, contribute to resistance to anti-cancer therapy.
Recently, many studies have shown that cancer-associated fibroblasts have significantly
contributed to angiogenesis in tumor, tumor’s growth, invasion and metastasis (Kalluri and
Zeisberg, 2006). Stroma also increases IFP, leading to low penetration of drug in the tumor
(Heldin et al., 2004). Using nanoparticulate formulation to remodel the tumor
microenvironment may be a powerful strategy to sensitize tumor cells to chemotherapy. Co-
delivery of stromal cell inhibitor and chemo-drugs to remodel the tumor microenvironment
has already shown very potent effects on the growth of tumor (Olive et al., 2009; Pietras et
al., 2002).
Drug combination with synergistic effect against cancer will be another strategy to
maximize the anti-cancer efficacy. Drug combination may exhibit synergistic or antagonistic
effect, depending on the doses and ratio of the two drugs (Chou, 2010). To deliver drug
combination at optimal ratio to the tumor, both drugs co-encapsulated in a single
formulation is highly desirable. More importantly, the ratio of released drugs from single
formulations need be precisely controlled at the optimal ratio. The choice of drugs for
combination therapy can be difficult. It has been largely a trial-and-error attempt. Recent
advances in genetic expression profiling and bioinformatics should give a rational base for
the choice (Lee et al., 2012b). Co-encapsulating two or more drugs in a single delivery
system can be problematic. For example, the drugs in optimal combination may differ in
solubility. Formulations which can deliver multiple drugs with diverse physicochemical
properties are also desired.
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The structure of polymeric micelles, polymeric nanoparticles, and polymer-drug conjugates.
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Preparation of lipid/calcium/phosphate (LCP) nanoparticles. Soluble calcium ion and siRNA
are mixed and distributed in one emulsion. Dioleoylphosphatydic acid (DOPA) and
Phosphate salt (pH=9.0) is distributed in another counter emulsion. SiRNA will be
encapsulated into calcium phosphate (CaP) cores when two emulsions are combined. The
DOPA stabilized CaP cores are further hydrated using another layer of outer leaflet lipid.
Reproduced with permission from reference (Li et al., 2012). Copyright 2012 Elsevier.
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Gemcitabine triphosphate, gemcitabine bioactive form, was encapsulated into Lipid/
Calcium/Phosphate nanoparticle (LCP) prepared in microemulsion. More chemo drugs with
phosphate group(s) could be entrapped into LCPs and delivered systemically using this
technology. (A) The chemical structure of GTP (Gemcitabine triphosphate
tris(triethylammonium) salt) used in this study. (B) TEM image of GTP-loaded LCPs.
Reproduced with permission from reference (Zhang, Kim, 2013). Copyright 2013 Elsevier.
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Schematic representation of the formulation of iron oxide nanoparticles and the process of
drug loading. Reproduced with permission from reference (Jain et al., 2005). Copyright
2005 American Chemical Society.
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Covalent coupling of paclitaxel to 4-mercaptophenol-modified 2 nm gold nanoparticles.
Reproduced with permission from reference (Gibson et al., 2007). Copyright 2007 American
Chemical Society.
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Table 1
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Table 2
Nanomedicines on the market and under clinical evaluation.








Samyang Co. Approved in Asia for treatment of breast and lung
cancers (Lee, Chung, 2008b; Lim, Tan, 2010);
Combinational therapy with gemcitabine and
cisplatin to treat advanced urothelial cancer currently













Usage for treating advanced or metastatic cancer
currently in Phase I clinical trial (Cartwright, 2013;








Usage for treatment of solid tumors currenlty in
Phase II clinical trial (Japan)
Abraxane® Albumin-bound paclitaxel
nanoparticle







Usage for treating non-resectable stage IVb
adenocarcinoma currently in Phase II clinical trial










Usage for treating breast, lung and colorectal cancer
currently in Phase II (UK) (Seymour, Ferry, 2009)




Combination with Gemcitabin or Vinorelbine to treat
Naïve Advanced Non-small Cell Lung Cancer in
currently in Phase III clinical trial (O'Brien, Socinski,
2008)




Treatment for advanced solid malignancies currently







Usage for treatment of advanced NSCLC currently in












Usage for treatment for solid tumors currently in






Combination with cisplatin to treat advanced or










Treats Kaposi’s sarcoma; metastatic breast &ovarian
cancers, FDA approved (Barenholz, 2012)
DaunoXom
e®
Liposomal daunorubicin Galen Ltd. Treats HIV-associated Kaposi’s sarcoma, FDA
approved (Fassas and Anagnostopoulos, 2005)




Treats metastatic breast cancer, Marketed (EU)






Treatment for metastatic pancreatic cancer, currently
in Phase 3 clinical trial (Ko, Tempero, 2013; Roy et al.,
2013)
OSI-211 Liposomal lurtotecan Astellas Pharma
Inc.
Treatment for recurrent small cell lung cancer,
currenlty in Phase 2 clinical trial (Duffaud et al., 2004)
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Celsion Corp. Treatment for primary liver cancer, currenlty in Phase
3 clinical trial (Dromi et al., 2007)
LEP-ETU Liposomal paclitaxel Insys
Therapeutics,
Inc.
Treatment for metastatic breast cancer, currently in





EntreMed Treatment for Metastatic carcinoid tumors, currently
in Phase II clinical trial (Bruce et al., 2012; Kulke et al.,
2011)
Theralux™ Nanocrystal formulation of
thymectacin
Celmed Treats metastatic breast cancer, Marketed (US, EU)
(Shegokar and Muller, 2010)
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